QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text Full Text (PDF) An erratum has been published Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (35) Citing Articles via Google Scholar Google Scholar Articles by Blakely, R. D. Search for Related Content PubMed PubMed Citation Articles by Blakely, R. D. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Antidepressants

 Previous Article  |  Next Article 

The Journal of Neuroscience, November 1, 2001, 21(21):8319-8323

Physiological Genomics of Antidepressant Targets: Keeping the Periphery in Mind

Randy D. Blakely

Department of Pharmacology, Center for Molecular Neuroscience, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6420

The plasma membrane transporters that clear extracellular serotonin (5-HT) and norepinephrine (NE), serotonin transporters (SERTs) and NE transporters (NETs), have received considerable attention over the past four decades because of their roles in amine neurotransmitter inactivation. In addition, they interact with many centrally active drugs, including multiple classes of antidepressants such as the serotonin-selective reuptake inhibitors, typified by fluoxetine (Prozac), and the more recently developed norepinephrine-selective transporter antagonists, such as reboxetine. The therapeutic utility of these agents supports biogenic amine theories of affective disorders and raises the question as to whether SERT and NET exhibit a functional genetic variation that could influence risk for behavioral disorders. Although evidence exists that a promoter polymorphism in SERT may influence behavioral states, this contention is not without complexity and its mechanism of action remains poorly understood. The identification of coding variants of NETs and SERTs would offer important opportunities to connect genotype to phenotype. However, given the limited frequency of transporter coding variations evident to date in general population surveys or in psychiatric genetic studies, the identification of informative functional variants of transporters will likely require refined phenotypes. In this regard, NET and SERT play critical roles in cardiovascular and gastrointestinal physiology, respectively. This perspective reviews recent human and mouse studies that suggest how peripheral autonomic phenotypes, linked to genetic disruption of NET and SERT function, can aid in the phenotypic segregation needed for advanced theories of biogenic amine dysfunction and pharmacogenetics.

Key words: norepinephrine; serotonin; transport; antidepressant; genetics; orthostatic intolerance; irritable bowel syndrome; serotonin-selective reuptake inhibitor; polymorphism, single-nucleotide polymorphism

---

Copyright © 2001 Society for Neuroscience  0270-6474/01/21218319-05$05.00/0

This article has been cited by other articles:

				B. Eisensamer, M. Uhr, S. Meyr, G. Gimpl, T. Deiml, G. Rammes, J. J. Lambert, W. Zieglgansberger, F. Holsboer, and R. Rupprecht Antidepressants and Antipsychotic Drugs Colocalize with 5-HT3 Receptors in Raft-Like Domains J. Neurosci., November 2, 2005; 25(44): 10198 - 10206. [Abstract] [Full Text] [PDF]

				M. P. Fleck and E. Horwath Pharmacologic Management of Difficult-to-Treat Depression in Clinical Practice Psychiatr Serv, August 1, 2005; 56(8): 1005 - 1011. [Abstract] [Full Text] [PDF]

				M. K. Hahn, M. S. Mazei-Robison, and R. D. Blakely Single Nucleotide Polymorphisms in the Human Norepinephrine Transporter Gene Affect Expression, Trafficking, Antidepressant Interaction, and Protein Kinase C Regulation Mol. Pharmacol., August 1, 2005; 68(2): 457 - 466. [Abstract] [Full Text] [PDF]

				J. W. Schwartz, G. Novarino, D. W. Piston, and L. J. DeFelice Substrate Binding Stoichiometry and Kinetics of the Norepinephrine Transporter J. Biol. Chem., May 13, 2005; 280(19): 19177 - 19184. [Abstract] [Full Text] [PDF]

				M Camilleri Is there a SERT-ain association with IBS? Gut, October 1, 2004; 53(10): 1396 - 1399. [Full Text] [PDF]

				A. K. Malhotra, G. M. Murphy Jr., and J. L. Kennedy Pharmacogenetics of Psychotropic Drug Response Am J Psychiatry, May 1, 2004; 161(5): 780 - 796. [Abstract] [Full Text] [PDF]

				D. L. Murphy, A. Lerner, G. Rudnick, and K.-P. Lesch Serotonin Transporter: Gene, Genetic Disorders, and Pharmacogenetics Mol. Interv., April 1, 2004; 4(2): 109 - 123. [Abstract] [Full Text] [PDF]

				M. K. Hahn, D. Robertson, and R. D. Blakely A Mutation in the Human Norepinephrine Transporter Gene (SLC6A2) Associated with Orthostatic Intolerance Disrupts Surface Expression of Mutant and Wild-Type Transporters J. Neurosci., June 1, 2003; 23(11): 4470 - 4478. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help